Limited Competition Data Coordinating Center for Type 1 Diabetes TrialNet (UC4) | Apply Online

Opportunity Summary:

The NIH funding opportunity RFA-DK-14-507, titled "Limited Competition Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)," is a discretionary cooperative agreement intended to support the Data Coordinating Center (DCC) for Type 1 Diabetes TrialNet, a large multicenter clinical research network focused on prevention and early intervention in type 1 diabetes. The award mechanism is a UC4 cooperative agreement, which signals substantial involvement and partnership with NIH staff during the project period, rather than a standard investigator-initiated grant with minimal federal involvement. The announcement is explicitly a limited competition: only the current awardee(s) operating the existing TrialNet Coordinating Center under the prior FOA (RFA-DK-12-503) are eligible to apply, meaning the intent is continuity of leadership and infrastructure for an established, complex coordinating operation rather than opening the role to new institutions.

The central purpose of the award is to maintain and expand the DCC functions that allow TrialNet studies to operate efficiently, consistently, and at scale across many sites and studies. In practical terms, the DCC is expected to provide the backbone for TrialNet research by managing data and biospecimen-related operations across a portfolio of projects that may be at different stages, from design to active enrollment to closeout and analysis. The FOA emphasizes end-to-end data and sample management responsibilities, including standardized acquisition procedures, quality control systems, dissemination pathways, and public accessibility of data and materials where appropriate. That language reflects a strong expectation for harmonized, high-integrity data capture and specimen handling, along with clear plans for sharing and making outputs accessible to the broader research community consistent with NIH policies.

Beyond sustaining core coordinating responsibilities, this FOA is meant to fund several new or expanded activities designed to keep TrialNet scientifically current and operationally effective. A major new element is support for a Biomarker and Mechanisms Panel, which would help design and potentially implement mechanistic studies that leverage TrialNet participants and the extensive collection of TrialNet biospecimens. Mechanistic and biomarker work is highlighted because TrialNet is uniquely positioned to study individuals at elevated risk for type 1 diabetes, as well as those in early or atypical disease stages, enabling analyses that are difficult to perform in routine clinical populations. The DCC is expected to facilitate this work by making sure participant data and samples can be linked, curated, quality-controlled, and analyzed in a way that produces interpretable, reproducible results.

The FOA also prioritizes improved recruitment and collaboration across the TrialNet ecosystem, specifically calling out partnership with the Clinical Network Hub. This reflects an operational emphasis: prevention and early-intervention trials depend on identifying and enrolling eligible at-risk individuals efficiently, often requiring coordinated screening, outreach strategies, site support, and consistent communication among clinical sites and coordinating entities. The DCC is therefore expected not just to passively manage databases, but to actively support approaches that make TrialNet recruitment more effective and that strengthen collaboration structures so that protocols can be launched and executed smoothly.

Another core objective is to support the design and conduct of new prevention trials, selected by the TrialNet Steering Committee, including trials that replace ongoing studies as they complete or that target newly described at-risk populations. This points to TrialNet as an adaptive platform where the trial portfolio evolves based on emerging science, completed studies, and new opportunities for intervention. The DCC role here includes enabling protocol development logistics, statistical and data coordination planning, trial operations support, and the data systems needed to run new multicenter studies. The announcement further calls for support for designing and conducting new studies in a "silent diabetes" population, also selected by the Steering Committee. While the FOA text does not define the term in detail, it signals a research emphasis on individuals who may have underlying disease processes or risk markers without obvious clinical symptoms, requiring careful identification, classification, monitoring, and analysis, all of which depend heavily on strong coordinating center functions.

Importantly, the FOA notes that in the final two years of the award, funds will continue ongoing TrialNet efforts, reinforcing that the award is structured to both introduce new capabilities and maintain long-term continuity of network operations. This is consistent with the reality that TrialNet runs multiple complex studies simultaneously, so the DCC must support both innovation (new panels, new trial concepts, new populations) and steady-state functions (data cleaning, monitoring, reporting, sample tracking, and study closeout activities).

From an administrative and funding standpoint, the opportunity was posted on August 21, 2014, with an original and current closing date of December 3, 2014, and an archive date of January 3, 2015. NIH anticipated making a single award (ExpectedAwards: 1), with an estimated total funding level up to $45,000,000 and an award ceiling matching that amount, indicating substantial, multi-year support commensurate with the scale of a national or international clinical trials network coordinating center. There is no cost sharing or matching requirement. The CFDA listing is 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), and the sponsoring agency is the National Institutes of Health, aligning the FOA with NIDDK-supported infrastructure for diabetes clinical research.

In short, this FOA is designed to ensure that TrialNet retains a highly capable Data Coordinating Center that can both maintain the day-to-day operational backbone of the network and expand into new scientific and operational areas, particularly biomarker and mechanistic research support, improved recruitment and collaboration, and the launch of new prevention and early-disease studies as directed by the TrialNet Steering Committee, all while ensuring data and biospecimens are collected, curated, quality-controlled, and shared in standardized and publicly accessible ways.

Browse more business programs for Diabetes Research

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Food and Nutrition Health

Next opportunity: Development of Visitor based Acoustical Indicators and Standards

Previous opportunity: FY15 Coral Reef NGO Partnership

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DK 14 507

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DK 14 507) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 14 507", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.